NOXAFIL POWDERMIX KIT Drug Patent Profile

« Back to Dashboard

When do Noxafil Powdermix Kit patents expire, and when can generic versions of Noxafil Powdermix Kit launch?

Noxafil Powdermix Kit is a drug marketed by Msd Merck Co and is included in one NDA.

The generic ingredient in NOXAFIL POWDERMIX KIT is posaconazole. There is one drug master file entry for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the posaconazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Noxafil Powdermix Kit

A generic version of NOXAFIL POWDERMIX KIT was approved as posaconazole by SINOTHERAPEUTICS INC on August 21^st, 2019.

Summary for NOXAFIL POWDERMIX KIT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Applications:	2,093
DailyMed Link:	NOXAFIL POWDERMIX KIT at DailyMed

Pharmacology for NOXAFIL POWDERMIX KIT

Drug Class

Azole Antifungal

US Patents and Regulatory Information for NOXAFIL POWDERMIX KIT

NOXAFIL POWDERMIX KIT is protected by zero US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Merck Co	NOXAFIL POWDERMIX KIT	posaconazole	FOR SUSPENSION, DELAYED RELEASE;ORAL	214770-001	May 31, 2021		RX	Yes	Yes

EU/EMA Drug Approvals for NOXAFIL POWDERMIX KIT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp and Dohme B.V	Noxafil	posaconazole	EMEA/H/C/000610Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.	Authorised	no	no	no	2005-10-25
Accord Healthcare S.L.U.	Posaconazole AHCL	posaconazole	EMEA/H/C/005028Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	Authorised	yes	no	no	2019-07-25
Accord Healthcare S.L.U.	Posaconazole Accord	posaconazole	EMEA/H/C/005005Posaconazole Accord is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole Accord is also indicated for prophylaxis of invasive fungal infections in the following patients: Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	Authorised	yes	no	no	2019-07-25

Noxafil PowderMix Kit Market Dynamics, Revenue Outlook, Patents, and Generic Risk

Last updated: October 25, 2026

Noxafil PowderMix Kit is Merck's posaconazole oral formulation for preventing invasive Aspergillus and Candida infections in severely immunocompromised patients. Its commercial value is tied to the broader Noxafil franchise, which also includes delayed-release tablets, oral suspension, and intravenous injection. Merck does not separately report PowderMix Kit revenue, prescription volume, or operating margin.

The product has a specialized hospital and transplant-market profile rather than a mass-market commercial base. Demand is supported by high-risk hematology, oncology, and transplant patients, but long-term growth faces generic competition, substitution by tablets and injectable therapy, institutional purchasing pressure, and the absence of separately reported product economics.

What is Noxafil PowderMix Kit and how is it used?

Noxafil PowderMix Kit contains posaconazole, a triazole antifungal. The product is supplied as a powder that is mixed with water before oral administration. It is used for prophylaxis against invasive Aspergillus and Candida infections in patients who are severely immunocompromised because of conditions such as prolonged neutropenia or hematopoietic stem-cell transplantation.[1]

The formulation is designed for patients who may have difficulty swallowing tablets or who require an alternative to the conventional oral suspension. Posaconazole exposure is clinically important because inadequate absorption can reduce antifungal protection.

Noxafil product presentations

Product	Route or dosage form	Commercial role
Noxafil PowderMix Kit	Powder for delayed-release oral suspension	Oral option for patients who need a liquid preparation
Noxafil delayed-release tablets	Oral tablet	Frequently preferred when patients can swallow tablets
Noxafil oral suspension	Conventional liquid suspension	Older oral formulation with more administration and absorption constraints
Noxafil injection	Intravenous	Hospital use when oral administration is not appropriate

The PowderMix formulation is not an independent active ingredient. Its market position depends on the clinical value of posaconazole and the ability of the presentation to retain patients within the Noxafil franchise.

What is the FDA regulatory status of Noxafil PowderMix Kit?

The FDA approved Noxafil in 2006, initially as an oral suspension. The agency later approved delayed-release tablets and intravenous posaconazole, followed by the PowderMix presentation.[1]

The PowderMix product is regulated under an approved new drug application and is marketed as a branded prescription antifungal. Its label includes prophylaxis indications rather than treatment of all invasive fungal infections. The product is not a biologic and does not face biosimilar competition.

Key FDA milestones

Milestone	Approximate timing
Initial Noxafil approval	2006
Delayed-release tablet approval	2013
Intravenous formulation approval	2014
PowderMix oral formulation approval	2018
Current regulatory framework	NDA-based branded drug

FDA approval of multiple dosage forms gave Merck a way to address different hospital and patient-use settings. The commercial effect is mixed: the broader franchise can defend posaconazole utilization, but sales can migrate among Noxafil presentations instead of creating entirely new demand.

What patents protect Noxafil PowderMix Kit?

Noxafil's protection has historically included patents covering posaconazole, pharmaceutical compositions, dosage forms, delayed-release technology, and methods of use. The relevant protection differs by presentation and jurisdiction.

The original compound and early formulation rights are substantially older than the PowderMix product. Later formulation patents can extend commercial protection for a specific presentation even after basic compound protection expires. The practical question for generic entrants is whether they can avoid later-listed formulation and method-of-use claims while obtaining FDA approval.

Patent categories affecting the product

Patent category	Commercial significance
Posaconazole compound patents	Protected the active pharmaceutical ingredient during the original exclusivity period
Oral formulation patents	Covered suspension composition, stability, solubility, or bioavailability
Delayed-release tablet patents	Protected tablet release characteristics and exposure profile
PowderMix formulation patents	May cover powder composition, reconstitution, stability, or administration
Method-of-use patents	May cover prophylaxis in defined immunocompromised populations
Manufacturing patents	Can raise technical barriers if the process is difficult to reproduce

The FDA Orange Book is the controlling source for listed U.S. patents and regulatory exclusivity associated with approved Noxafil presentations.[2] Patent listings can change through updates, litigation outcomes, terminal disclaimers, pediatric extensions, or delisting.

When does Noxafil PowderMix Kit lose exclusivity?

Noxafil's original market exclusivity has expired. The timing of generic entry for PowderMix depends on the specific NDA, Orange Book-listed patents, any Paragraph IV challenges, and whether a generic applicant seeks approval for the powder formulation itself or another posaconazole dosage form.

The product does not have biologic exclusivity. It also does not receive the extended regulatory protection associated with a new biologic reference product.

Exclusivity drivers

Exclusivity factor	Effect on market entry
New chemical entity exclusivity	Expired for the original Noxafil approval
Pediatric exclusivity	May add six months to applicable patent or exclusivity periods when awarded
Formulation patents	Can delay a generic that copies the same dosage form
Method-of-use patents	May require a section viii carve-out or litigation
Regulatory exclusivity for later formulation	Depends on the approval basis and FDA designation
Patent settlements	Can establish an agreed generic launch date

A precise PowderMix generic-entry date cannot be inferred from Noxafil's original approval date. The relevant date is the latest enforceable patent or settlement restriction attached to the specific product and proposed generic product.

What is the Orange Book status of Noxafil PowderMix Kit?

Noxafil products are prescription drugs subject to Orange Book patent-listing analysis. The Orange Book distinguishes among approved dosage forms and strengths, which matters because patents listed for tablets or injection may not block a generic powder formulation.

A generic applicant may file an abbreviated new drug application with:

• A Paragraph III certification accepting delayed approval until patent expiry.
• A Paragraph IV certification asserting that listed patents are invalid, unenforceable, or not infringed.
• A section viii statement carving out patented methods of use.
• A suitability or formulation strategy that avoids the reference product's protected characteristics.

The PowderMix product's generic risk is therefore more complex than a simple compound-patent expiry analysis. The key commercial question is whether a generic can replicate the clinical exposure, stability, reconstitution process, and manufacturing economics at acceptable cost.

Which companies are challenging Noxafil patents?

Public generic competition has focused broadly on posaconazole products, particularly the oral tablet market. Generic drugmakers that participate in the antifungal market include Teva, Lupin, Dr. Reddy's Laboratories, Zydus, and other ANDA sponsors, depending on the dosage form and market jurisdiction.

The presence of a generic posaconazole tablet does not establish an approved generic for Noxafil PowderMix Kit. Each dosage form has separate pharmaceutical and regulatory requirements. A tablet entrant can reduce franchise pricing without directly replacing the PowderMix presentation.

Paragraph IV risk

A Paragraph IV challenge can create patent litigation under the Hatch-Waxman Act. If the NDA holder sues within the statutory period, FDA approval of the ANDA may be subject to a 30-month stay, subject to court decisions and statutory exceptions.[3]

For PowderMix, the most important litigation issues would likely include:

1. Whether the generic has the same powder and reconstitution characteristics.
2. Whether formulation claims are valid and infringed.
3. Whether a proposed label induces use covered by method-of-use claims.
4. Whether the generic can obtain approval through a section viii carve-out.
5. Whether the applicant has challenged patents covering the reference product or only another posaconazole dosage form.

How strong is the Noxafil patent estate?

The Noxafil patent estate is weaker against broad molecule-level competition than it was during the first decade after launch. Its remaining commercial strength depends on formulation and presentation-specific protection.

Patent-strength assessment

Factor	Assessment
Active ingredient protection	Mature and largely exhausted
Clinical differentiation	Moderate, based on absorption and patient-use requirements
Tablet protection	More exposed to generic competition than during the original patent period
PowderMix protection	Potentially stronger if formulation claims are narrow but difficult to design around
Manufacturing barriers	Moderate; sterile injection production is more demanding than oral powder production
Litigation leverage	Dependent on current Orange Book listings and claim scope
Long-term durability	Limited by multiple alternative posaconazole presentations

The product's defensibility is strongest when the formulation solves a specific clinical problem that cannot be addressed easily by tablets or conventional suspension. That advantage is narrower than compound exclusivity and generally supports a shorter, more contested commercial life.

What is the market outlook for Noxafil PowderMix Kit?

The PowderMix market is concentrated in high-risk institutional care. Main demand sources include hematology-oncology centers, transplant programs, infectious-disease services, and hospitals managing patients with prolonged neutropenia.

Market demand drivers

• Growth in hematopoietic stem-cell transplantation.
• Increased use of mold-active antifungal prophylaxis.
• Recognition of invasive fungal disease risk in immunocompromised patients.
• Need for oral therapy when tablets cannot be swallowed.
• Continued use of posaconazole when drug exposure is clinically reliable.

Market constraints

• Generic posaconazole tablets can reduce price and shift prescribing.
• Hospitals use formularies and contract pricing to control antifungal expenditure.
• Patients may switch between Noxafil presentations during treatment.
• Posaconazole competes with isavuconazole, voriconazole, and other antifungal strategies.
• The PowderMix product addresses a narrower population than the entire posaconazole market.

The largest commercial opportunity is not necessarily volume expansion. It is retention of high-value patients within the branded Noxafil franchise when the PowderMix format offers a practical advantage over tablets or conventional suspension.

What are Noxafil's revenues and financial trajectory?

Merck does not publicly disclose net sales for Noxafil PowderMix Kit as a standalone product. It also does not consistently provide a separate revenue line for every Noxafil dosage form in its public financial statements.[4]

Noxafil economics are therefore analyzed through the broader Merck pharmaceutical portfolio, product-level commentary, prescription data, hospital procurement information, and generic-entry events. Any standalone PowderMix revenue estimate would be a modeled figure rather than a reported company result.

Financial trajectory

Period	Financial interpretation
2006-2012	Franchise expansion from initial oral suspension launch
2013-2017	Growth supported by delayed-release tablets and wider prophylaxis use
2018-2020	Portfolio expansion through the PowderMix presentation
2021-2024	Mature-brand phase with formulation substitution and generic pressure
Forward outlook	Greater price pressure and declining branded share, partly offset by institutional demand

Revenue exposure is concentrated in the overall posaconazole franchise, not in PowderMix alone. The product's contribution is likely smaller than that of tablets because PowderMix is a specialized presentation and the tablet is generally more convenient for patients who can swallow solid dosage forms.

Margin profile

PowderMix has the economics of a specialized branded oral product. Its gross margin is likely higher than that of a generic competitor, but net realized pricing is affected by:

• Hospital and group-purchasing contracts.
• Rebates and discounts.
• Specialty-distribution fees.
• Formulary positioning.
• Patient assistance and access programs.
• Manufacturing and packaging costs for powder sachets and reconstitution materials.

As generic tablets gain share, Merck may face franchise-level price compression even if PowderMix retains a protected niche.

How does Noxafil PowderMix compare with competing antifungal drugs?

Drug or class	Main advantage	Main commercial threat to Noxafil PowderMix
Posaconazole delayed-release tablet	Convenient oral administration and established exposure profile	Direct substitution within the Noxafil franchise or generic tablet competition
Posaconazole oral suspension	Liquid dosing and historical availability	Less predictable absorption and administration burden
Posaconazole injection	Reliable hospital delivery when oral dosing fails	Higher cost and intravenous administration
Isavuconazole	Alternative mold-active triazole	Clinical substitution and formulary competition
Voriconazole	Established antifungal use and generic availability	Lower-cost alternative in selected patients
Echinocandins	Established hospital use and intravenous delivery	Competition in treatment and prophylaxis protocols

PowderMix is most defensible when the patient needs an oral liquid but does not have a suitable tablet option. It is less defensible when the hospital can use a lower-cost generic tablet or an alternative antifungal regimen.

What generic launch scenarios exist for Noxafil PowderMix Kit?

Scenario 1: Generic tablets launch first

This is the most commercially important near-term risk to the franchise. Generic tablets can reduce average posaconazole prices and pressure Merck's negotiating position even without directly copying PowderMix.

Scenario 2: A direct PowderMix generic launches

A direct generic would target patients who need a liquid formulation. Market share could grow quickly in hospitals if the product is therapeutically substitutable and priced substantially below Noxafil.

Scenario 3: Delayed or limited entry

Formulation patents, manufacturing complexity, litigation, or limited commercial demand could delay direct PowderMix competition. In this case, the product could retain a niche position while the broader franchise loses share to generic tablets.

Scenario 4: Franchise migration

Merck may shift demand among tablets, suspension, injection, and PowderMix. This can protect posaconazole utilization while reducing the financial value of the branded presentation.

What licensing deals and manufacturing barriers affect the product?

Noxafil originated from Schering-Plough's antifungal portfolio and is now commercialized by Merck following Merck's acquisition of Schering-Plough.[5] Public financial disclosures do not identify a material third-party licensing transaction dedicated specifically to PowderMix Kit.

Manufacturing barriers are meaningful but not prohibitive. The product requires controlled powder production, dose uniformity, stability, packaging, and validated reconstitution instructions. These requirements are less demanding than sterile injectable manufacturing but can still create scale and quality-control costs for smaller generic manufacturers.

Key Takeaways

• Noxafil PowderMix Kit is a specialized posaconazole oral formulation for high-risk immunocompromised patients.
• Merck does not separately report PowderMix revenue, market share, or profitability.
• The product's commercial value is linked to the broader Noxafil franchise.
• Original compound exclusivity is mature; remaining protection depends on formulation, method-of-use, and presentation-specific patents.
• Generic tablet competition can pressure Noxafil economics without requiring a direct PowderMix generic.
• The principal growth constraint is substitution by tablets, generic posaconazole, alternative triazoles, and hospital formulary controls.
• PowderMix is most commercially defensible in patients who need a liquid oral formulation and cannot use tablets.
• A direct generic launch would create greater share and price risk than ordinary franchise substitution.

FAQs

Is Noxafil PowderMix Kit the same as posaconazole oral suspension?

No. Both contain posaconazole, but PowderMix is a distinct powder-based oral formulation with separate preparation and administration requirements.

Does Noxafil PowderMix Kit have biosimilar competition?

No. Posaconazole is a small-molecule drug, so competition proceeds through the generic drug pathway rather than the biosimilar pathway.

Can a generic posaconazole tablet replace Noxafil PowderMix Kit?

Not for every patient. Patients who cannot swallow tablets or require a liquid oral preparation may still need PowderMix or another liquid formulation.

Is Noxafil PowderMix revenue disclosed by Merck?

No. Merck's public reporting does not provide a standalone revenue line for Noxafil PowderMix Kit.

What is the main investment risk for Noxafil PowderMix Kit?

The main risk is erosion of branded posaconazole economics through generic tablets, direct formulation competition, hospital purchasing pressure, and migration to alternative antifungal therapies.

References

1. U.S. Food and Drug Administration. (2024). Noxafil (posaconazole) prescribing information.
2. U.S. Patent and Trademark Office. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2023). Hatch-Waxman amendments and abbreviated new drug applications.
4. Merck & Co., Inc. (2024). 2023 annual report.
5. Merck & Co., Inc. (2009). Merck completes acquisition of Schering-Plough.